Phathom Pharmaceuticals Inc (NAS:PHAT)

Q2 2025 Phathom Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2025 / 12:00 PM GMT

Release Date Price: $9.4 (+8.29%)

Transcript 10-Q8-K

Key Points

Positve

Phathom Pharmaceuticals Inc (PHAT) reported a 39% increase in revenue for Q2 2025 compared to Q1, driven by increased adoption of their product.
The company achieved a positive resolution to their citizen's petition, securing exclusivity for their product until at least 2033.
Phathom Pharmaceuticals Inc (PHAT) has implemented cost-saving initiatives, resulting in a $12 million reduction in non-GAAP operating expenses compared to Q1.
The company has a strategic focus on gastroenterologists, which is expected to drive accelerated revenue growth.
Phathom Pharmaceuticals Inc (PHAT) ended the quarter with approximately $150 million in cash, which is expected to be sufficient to reach profitability without additional equity financing.

Negative

The company is facing a potential supply disruption for the Vuesna triple pack, which represents about 1% of total revenue.
There is a reliance on the Blink Rx cash pay option for Medicare patients, which may impact gross-to-net ratios.
Phathom Pharmaceuticals Inc (PHAT) has not yet forecasted or published a detailed 2026 operating expense run rate, creating some uncertainty.
The transition to focusing on gastroenterologists may take 2 to 3 quarters to show significant revenue acceleration.
The company is discontinuing its direct-to-consumer promotional program, which could impact brand awareness and patient activation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHAT.OQ - Phathom Pharmaceuticals Inc
Q2 2025 Phathom Pharmaceuticals Inc Earnings Call
Aug 07, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the Fathom Pharmaceuticals 2nd quarter 2025 earnings results call. At this time, all participants are on a listen-only mode. After this presentation, there'll be a question and answer session. To raise your hand, to ask the question, please press 11. To lower your hand, please press 11 again.

Please be advised that today's call is being recorded. With that, I'd like to turn the call over to Eric Shorrelli, fathoms head of investor relations, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Hello

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.